HRP20241073T1 - Virusni vektori koji sadrže kodirajuće regije rdh12 i postupci za liječenje distrofija mrežnice - Google Patents
Virusni vektori koji sadrže kodirajuće regije rdh12 i postupci za liječenje distrofija mrežnice Download PDFInfo
- Publication number
- HRP20241073T1 HRP20241073T1 HRP20241073TT HRP20241073T HRP20241073T1 HR P20241073 T1 HRP20241073 T1 HR P20241073T1 HR P20241073T T HRP20241073T T HR P20241073TT HR P20241073 T HRP20241073 T HR P20241073T HR P20241073 T1 HRP20241073 T1 HR P20241073T1
- Authority
- HR
- Croatia
- Prior art keywords
- adeno
- viral vector
- seq
- rdh12
- associated viral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01105—Retinol dehydrogenase (1.1.1.105)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762586624P | 2017-11-15 | 2017-11-15 | |
| EP18878835.0A EP3710590B1 (en) | 2017-11-15 | 2018-11-15 | Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies |
| PCT/US2018/061319 WO2019099696A1 (en) | 2017-11-15 | 2018-11-15 | Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20241073T1 true HRP20241073T1 (hr) | 2024-11-08 |
Family
ID=66431192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20241073TT HRP20241073T1 (hr) | 2017-11-15 | 2018-11-15 | Virusni vektori koji sadrže kodirajuće regije rdh12 i postupci za liječenje distrofija mrežnice |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20190142909A1 (enExample) |
| EP (2) | EP4364803A3 (enExample) |
| JP (2) | JP2021502978A (enExample) |
| KR (1) | KR102704296B1 (enExample) |
| CN (2) | CN117752822A (enExample) |
| AU (1) | AU2018367606B2 (enExample) |
| BR (1) | BR112020009828A2 (enExample) |
| DK (1) | DK3710590T3 (enExample) |
| EA (1) | EA202091194A1 (enExample) |
| ES (1) | ES2983990T3 (enExample) |
| FI (1) | FI3710590T3 (enExample) |
| HR (1) | HRP20241073T1 (enExample) |
| HU (1) | HUE068393T2 (enExample) |
| IL (2) | IL274609B2 (enExample) |
| LT (1) | LT3710590T (enExample) |
| MA (1) | MA50914A (enExample) |
| MX (1) | MX2020005008A (enExample) |
| MY (1) | MY204271A (enExample) |
| PH (1) | PH12020551319A1 (enExample) |
| PL (1) | PL3710590T3 (enExample) |
| PT (1) | PT3710590T (enExample) |
| RS (1) | RS65881B1 (enExample) |
| SG (1) | SG11202004527YA (enExample) |
| SI (1) | SI3710590T1 (enExample) |
| SM (1) | SMT202400321T1 (enExample) |
| WO (1) | WO2019099696A1 (enExample) |
| ZA (1) | ZA202003416B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL264070B2 (en) | 2016-07-08 | 2023-03-01 | Univ Pennsylvania | Methods and preparations for the treatment of disorders and diseases involving rdh12 |
| EP4329882A4 (en) * | 2021-04-27 | 2025-02-26 | The Trustees of Columbia University in the City of New York | METHODS AND COMPOSITIONS FOR REGULATING CHOLESTEROL EFFLUX TO PREVENT, TREAT OR CURE MACULAR DEGENERATION |
| CN115725659A (zh) * | 2022-04-01 | 2023-03-03 | 首都医科大学附属北京同仁医院 | 一种应用视网膜原位基因编辑制作非人灵长类动物先天性黑矇模型的方法 |
| CN118453915A (zh) * | 2024-04-29 | 2024-08-09 | 中国医学科学院北京协和医院 | 一种针对rdh12突变的基因治疗药物 |
| CN119432856B (zh) * | 2024-12-30 | 2025-08-12 | 云舟生物科技(广州)股份有限公司 | 核酸分子、病毒颗粒及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120172419A1 (en) * | 2009-09-15 | 2012-07-05 | Medical College Of Wisconsin Research Foundation Inc. | Reagents and methods for modulating cone photoreceptor activity |
| AU2011242527B2 (en) * | 2010-04-23 | 2016-05-19 | University Of Florida Research Foundation, Inc. | rAAV-guanylate cyclase compositions and methods for treating Leber's congenital amaurosis-1 (LCA1) |
| WO2012167109A2 (en) * | 2011-06-03 | 2012-12-06 | Massachusetts Eye & Ear Infirmary | Rpgrip1 gene therapy for leber congenital amaurosis |
| NZ704275A (en) * | 2012-07-11 | 2016-09-30 | Univ Florida | Aav-mediated gene therapy for rpgr x-linked retinal degeneration |
| PE20170260A1 (es) * | 2014-05-02 | 2017-04-12 | Genzyme Corp | Vectores de aav para la terapia genica de la retina y el snc |
| GB201412011D0 (en) * | 2014-07-04 | 2014-08-20 | Ucl Business Plc | Treatments |
| DK3821912T3 (da) * | 2014-07-24 | 2024-08-05 | Massachusetts Eye & Ear Infirmary | RPGR-genterapi mod retinitis pigmentosa |
| CA2979229A1 (en) * | 2015-03-11 | 2016-09-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Rp2 vectors for treating x-linked retinitis pigmentosa |
| EP4008780A1 (en) * | 2015-04-30 | 2022-06-08 | The Trustees of Columbia University in the City of New York | Gene therapy for autosomal dominant diseases |
| IL264070B2 (en) | 2016-07-08 | 2023-03-01 | Univ Pennsylvania | Methods and preparations for the treatment of disorders and diseases involving rdh12 |
-
2018
- 2018-11-15 WO PCT/US2018/061319 patent/WO2019099696A1/en not_active Ceased
- 2018-11-15 JP JP2020526473A patent/JP2021502978A/ja active Pending
- 2018-11-15 EP EP24163209.0A patent/EP4364803A3/en active Pending
- 2018-11-15 CN CN202311261068.0A patent/CN117752822A/zh active Pending
- 2018-11-15 HR HRP20241073TT patent/HRP20241073T1/hr unknown
- 2018-11-15 EA EA202091194A patent/EA202091194A1/ru unknown
- 2018-11-15 SM SM20240321T patent/SMT202400321T1/it unknown
- 2018-11-15 HU HUE18878835A patent/HUE068393T2/hu unknown
- 2018-11-15 FI FIEP18878835.0T patent/FI3710590T3/fi active
- 2018-11-15 MA MA050914A patent/MA50914A/fr unknown
- 2018-11-15 CN CN201880086649.6A patent/CN111886340A/zh active Pending
- 2018-11-15 SG SG11202004527YA patent/SG11202004527YA/en unknown
- 2018-11-15 IL IL274609A patent/IL274609B2/en unknown
- 2018-11-15 RS RS20240857A patent/RS65881B1/sr unknown
- 2018-11-15 PT PT188788350T patent/PT3710590T/pt unknown
- 2018-11-15 AU AU2018367606A patent/AU2018367606B2/en active Active
- 2018-11-15 BR BR112020009828-0A patent/BR112020009828A2/pt unknown
- 2018-11-15 IL IL308645A patent/IL308645B1/en unknown
- 2018-11-15 KR KR1020207016694A patent/KR102704296B1/ko active Active
- 2018-11-15 US US16/192,382 patent/US20190142909A1/en not_active Abandoned
- 2018-11-15 DK DK18878835.0T patent/DK3710590T3/da active
- 2018-11-15 LT LTEPPCT/US2018/061319T patent/LT3710590T/lt unknown
- 2018-11-15 ES ES18878835T patent/ES2983990T3/es active Active
- 2018-11-15 SI SI201831135T patent/SI3710590T1/sl unknown
- 2018-11-15 PL PL18878835.0T patent/PL3710590T3/pl unknown
- 2018-11-15 MX MX2020005008A patent/MX2020005008A/es unknown
- 2018-11-15 MY MYPI2020002341A patent/MY204271A/en unknown
- 2018-11-15 EP EP18878835.0A patent/EP3710590B1/en active Active
-
2020
- 2020-05-15 PH PH12020551319A patent/PH12020551319A1/en unknown
- 2020-06-08 ZA ZA2020/03416A patent/ZA202003416B/en unknown
-
2022
- 2022-08-09 US US17/818,623 patent/US20230190884A1/en active Pending
-
2023
- 2023-07-26 JP JP2023121924A patent/JP7615238B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20241073T1 (hr) | Virusni vektori koji sadrže kodirajuće regije rdh12 i postupci za liječenje distrofija mrežnice | |
| JP7182873B2 (ja) | 多重ベクターシステム及びその使用 | |
| JP2021502978A5 (enExample) | ||
| HRP20202023T1 (hr) | Genska terapija rpgr za liječenje retinitis pigmentose | |
| RU2019100525A (ru) | Векторная система на основе аденоассоциированного вируса | |
| JP2015523379A5 (enExample) | ||
| KR20160033217A (ko) | 변종 aav 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도 | |
| JP2017523239A5 (enExample) | ||
| US11339396B2 (en) | Engineered viral vector reduces induction of inflammatory and immune responses | |
| JP2019523648A5 (enExample) | ||
| JP2020073536A5 (enExample) | ||
| EP2262899A1 (en) | Method of treating genetic disorders | |
| FI3419672T3 (fi) | Geeniterapia verkkokalvon rappeumataudin hoitamiseksi | |
| JP2018526994A5 (enExample) | ||
| JP2018509154A5 (enExample) | ||
| HRP20241483T1 (hr) | Sastavi i postupci za liječenje poremećaja mrežnice | |
| US20170137480A1 (en) | Rpgr-ofr15 variant gene in the treatment of retinitis pigmentosa | |
| WO2018076125A1 (es) | Vacuna recombinante contra el circovirus porcino potenciada con un inmunomodulador | |
| CN111100847A (zh) | 安全性更高的端粒基因治疗产品使人体健康逆转衰老 | |
| JP2016512028A5 (enExample) | ||
| Sen et al. | 114. A Novel Adeno-Associated Virus Serotype (AAV)-8 Capsid Mutant Improves Human Coagulation Factor IX Expression In Vivo | |
| Stavrou et al. | 248. A Bona Fide Mammalian Replicator Enhances All Aspects of Episomal Gene Transfer Into Human Hematopoietic Progenitor Cells | |
| Mookherjee et al. | SENSORY (OPHTHALMIC AND AUDITORY) DISEASES | |
| Karimi et al. | Cloning of human factor 9 cDNA in AAV vector and assessment of its expression in HEK293T cells | |
| AU2020291000A1 (en) | Methods and compositions of astrovirus replicons |